BIOMAT Database Logo BIOMAT Database Logo

Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. 1988

H C Lane, and J A Kovacs, and J Feinberg, and B Herpin, and V Davey, and R Walker, and L Deyton, and J A Metcalf, and M Baseler, and N Salzman
Laboratory of Immunoregulation and Treatment Branch, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland.

21 patients with AIDS and Kaposi's sarcoma were enrolled in an open therapeutic trial to determine the in vivo anti-retroviral activity of recombinant interferon-alpha (IFN-alpha). 8 (38%) showed a complete or partial anti-tumour response. The mean pretreatment CD4 count for the responders was 399 cells/microliter vs 154 cells/microliter for the non-responders. All 5 of the patients with more than 400 CD4 cells/microliter pretreatment showed a significant reduction in tumour, whereas none of the 7 patients with under 150 CD4 cells/microliter had any response. 5 of the 6 complete or partial responders with greater than 50 pg/ml of human immunodeficiency virus (HIV) p24 before IFN therapy showed a 75% or greater reduction by 12 weeks of therapy, with 3 patients having persistently negative HIV cultures. The anti-viral effects were also most pronounced in the patients with the highest CD4 counts. These data demonstrate the potential benefits, both anti-tumour and anti-retroviral, of treatment with IFN-alpha in the early stages of HIV infection and Kaposi's sarcoma.

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

H C Lane, and J A Kovacs, and J Feinberg, and B Herpin, and V Davey, and R Walker, and L Deyton, and J A Metcalf, and M Baseler, and N Salzman
Alpha interferon therapy of AIDS-associated Kaposi's sarcoma.
September 1986, Seminars in oncology,
H C Lane, and J A Kovacs, and J Feinberg, and B Herpin, and V Davey, and R Walker, and L Deyton, and J A Metcalf, and M Baseler, and N Salzman
Alpha interferon therapy of AIDS-associated Kaposi's sarcoma.
June 1987, Seminars in oncology,
H C Lane, and J A Kovacs, and J Feinberg, and B Herpin, and V Davey, and R Walker, and L Deyton, and J A Metcalf, and M Baseler, and N Salzman
Interferon-alpha: evolving therapy for AIDS-associated Kaposi's sarcoma.
April 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research,
H C Lane, and J A Kovacs, and J Feinberg, and B Herpin, and V Davey, and R Walker, and L Deyton, and J A Metcalf, and M Baseler, and N Salzman
Interferon alpha in the treatment of AIDS-associated Kaposi's sarcoma.
February 1987, Onkologie,
H C Lane, and J A Kovacs, and J Feinberg, and B Herpin, and V Davey, and R Walker, and L Deyton, and J A Metcalf, and M Baseler, and N Salzman
Treatment of AIDS-associated Kaposi's sarcoma with recombinant alpha interferon.
September 1986, Immunobiology,
H C Lane, and J A Kovacs, and J Feinberg, and B Herpin, and V Davey, and R Walker, and L Deyton, and J A Metcalf, and M Baseler, and N Salzman
Alpha interferon therapy of Kaposi's sarcoma in AIDS.
January 1984, Annals of the New York Academy of Sciences,
H C Lane, and J A Kovacs, and J Feinberg, and B Herpin, and V Davey, and R Walker, and L Deyton, and J A Metcalf, and M Baseler, and N Salzman
Low incidence of anti-interferon-alpha antibodies in patients treated with interferon-alpha-2a for AIDS-associated Kaposi's sarcoma.
July 1990, International journal of STD & AIDS,
H C Lane, and J A Kovacs, and J Feinberg, and B Herpin, and V Davey, and R Walker, and L Deyton, and J A Metcalf, and M Baseler, and N Salzman
Alpha interferon approved for AIDS-related Kaposi's sarcoma.
January 1989, Oncology (Williston Park, N.Y.),
H C Lane, and J A Kovacs, and J Feinberg, and B Herpin, and V Davey, and R Walker, and L Deyton, and J A Metcalf, and M Baseler, and N Salzman
Interferon alpha in the treatment of AIDS-related Kaposi's sarcoma.
October 1991, British journal of haematology,
H C Lane, and J A Kovacs, and J Feinberg, and B Herpin, and V Davey, and R Walker, and L Deyton, and J A Metcalf, and M Baseler, and N Salzman
Combined zidovudine and interferon-alpha treatment in patients with AIDS-associated Kaposi's sarcoma.
January 1991, Journal of internal medicine,
Copied contents to your clipboard!